semaglutide cagrilintide Efficacy and safety of co-administered once-weekly 2·4 mg with once-weekly 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial Cagrilintide and semaglutide act individually

Potential long-term risks such as pancreatitis, gallbladder disease, and lean muscle mass loss are still being evaluated in ongoing Phase 3 trials

Jumping to higher doses too quickly causes severe nausea that leads patients to quit entirely

Our analysis is consistent with studies demonstrating that obesity, and particularly a high BMI, among patients with diabetes is a common characteristic of patients with rapid GET [28, 29]

This coincides with the democratization of GLP-1 peptides

Common Side Effects and How to Manage Them Nausea is the most frequently reported side effect during the first few weeks, affecting about 25-30% of users, but it rarely lasts beyond the first month as your digestive system adapts